Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenzaGen ABOSTO:SENZA -0.75%72 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates OSTO:SENZA with a GF Score™ of 72/100 and a GF Value™ of kr6.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, SenzaGen AB ranks worse than 1075267.74% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. SenzaGen AB's
Operating Income
for the
three
months ended in Mar. 2026 was kr-2.12 Mil. SenzaGen AB's Interest Expense for the
three
months ended in Mar. 2026 was kr-0.37 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for SenzaGen AB's Interest Coverage or its related term are showing as below:
OSTO:SENZA's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.26 * Ranked among companies with meaningful Interest Coverage only.
SenzaGen AB (OSTO:SENZA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
SenzaGen AB Interest Coverage Related Terms
SenzaGen AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OSTO:SENZA vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
SenzaGen AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
SenzaGen AB (OSTO:SENZA) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry.
Is SenzaGen AB's Interest Coverage too high?
SenzaGen AB's current Interest Coverage is 0 (At Loss). Based on the distribution chart, SenzaGen AB ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, SenzaGen AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #999999 out of 93 companies for Interest Coverage. This places SenzaGen AB in the lower half of its industry. The industry median Interest Coverage is 9.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.26, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SenzaGen AB and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
Based on GuruFocus' analysis, SenzaGen AB (OSTO:SENZA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr6.41, compared to a current price of kr5.30 — trading 17.3% below its estimated fair value. The current Interest Coverage is 0 (At Loss). SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For SenzaGen AB (OSTO:SENZA), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (OSTO:SENZA) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of kr5.30 is trading 17.3% below its estimated GF Value™ of kr6.41.
GuruFocus considers SenzaGen AB to be Modestly Undervalued.
Key valuation signals for OSTO:SENZA:
Interest Coverage: 0 (At Loss)
GF Value™: kr6.41 vs. price of kr5.30 (17.3% below fair value)
No single metric tells the full story. See the OSTO:SENZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for OSTO:SENZA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SENZA has been successfully added to your 
